Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed results and operational updates relevant to investors
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net income $14.2M, or $0.71 basic EPS, versus $7.3M loss, driven by $40.0M license revenue
- Nine-month net loss $38.3M despite $40.0M license revenue, highlighting continued operating losses without partnering income
- Rinvatercept Phase 2 DMD trial dosed its first patient, with initial data expected in the first half of 2027
- KER-206 nominated for further investigation, expanding Keros’ pipeline into bone-loss disorders
- Cash $259.5M, down from $287.4M at December 31, 2025, with runway projected into the second half of 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.